Table 2. Baseline characteristics of enrolled patients.

Total	No. of patients (%)	Captured CTC/mL
	61 (100)	A cells (DAPI+/E&M+/CD45-/HE4+)	B cells (DAPI+/E&M-/CD45-/HE4+)	C cells (DAPI+/E&M+/CD45-/HE4-)
Tumor stage (Kruskal-Wallis test)		p = 0.064	p = 0.105	p = 0.742
Benign	25 (41.0)	0.8 ± 1.5 (0–6)	0.1 ± 0.6 (0–3)	2.7 ± 6.6 (0–31)
Stage I	8(13.2)	2.1 ± 1.8 (0–6)	0.0 ± 0.0 (0–0)	2.5 ± 3.4 (0–8)
Stage II	4 (6.6)	2.0 ± 2.1 (0–5)	0.3 ± 0.5 (0–1)	2.0 ± 2.4 (0–5)
Stage III	16 (26.4)	2.3 ± 2.5(0–8)	0.06 ± 0.3 (0–1)	2.3 ± 4.2 (0–15)
Stage IV	2 (3.3)	1.0 ± 1.4 (0–2)	0.5 ± 0.71 (0–1)	0.0 ± 0.0 (0)
Other malignant diseases	6 (9.8)	0.5 ± 0.8 (0–2)	0.0 ± 0.0 (0–0)	2.8 ± 4.2 (0–11)
Macroscopic residual disease* (t-test)		p = 0.741	p = 0.364	p = 0.776
Yes	10 (34.5)	2.2 ± 2.3 (0–8)	0.1 ± 0.3 (0–1)	2.4 ± 3.2 (0–10)
No	19 (65.5)	2.1 ± 2.2 (0–7)	0.1 ± 0.2 (0–1)	2.2 ± 3.9 (0–15)
Lymph node involvement* (ANOVA)		p = 0.53	p <0.001	p = 0.117
Yes	7 (23.3)	3.0 ± 2.5 (0–7)	0.1 ± 0.4 (0–1)	3.0 ± 5.4 (0–15)
No	17 (56.7)	2.1 ± 2.3 (0–8)	0.0 ± 0.0 (0)	2.4 ± 3.3 (0–10)
Unmeasured†	6 (20)	1.3 ± 1.2 (0–3)	0.3 ± 0.5 (0–1)	0.5 ± 1.2 (0–3)
CA-125 (t-test)		p = 0.966	p = 0.635	p = 0.724
≤ 35 U/mL	21 (36.7)	1.5 ± 2.2 (0–8)	0.1 ± 0.7 (0)	1.7 ± 3.4 (0–15)
> 35 U/mL	36 (63.3)	1.5 ± 1.9 (0–7)	0.1 ± 0.3 (0–1)	2.1 ± 3.5 (0–10)

^*Benign samples were not included for these characteristics.

^†Did not undergo the surgery or lymph node dissection.